The Global Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type (Standard PTA Balloons, High Pressure PTA Balloons, Scoring PTA Balloons, Cutting Balloons, Drug Coated Balloon, Lithotripsy Balloons, and Others (Stent graft balloon catheter)), by Material (Polyurethane, Nylon, and Others), by Application (Peripheral Artery Disease and Coronary Artery Disease), by Diameter Size (1 to 4 mm, 4 to 8 mm, and > 8 mm), by End User (Hospitals, Cardiology Clinics, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,435.0 million in 2021 and expected to exhibit a CAGR of 8.3% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
The increasing number of product launches by the key market players is expected to drive the global percutaneous transluminal angioplasty balloons catheter market growth over the forecast period. For instance, in April 2019, BD (Becton, Dickinson and Company), a leading global medical technology company, announced the launch of UltraScore 014 Focused Force PTA Balloon in the U.S. market. This device is indicated to dilate stenoses in the femoral, iliac, iliofemoral, renal, popliteal, and infra-popliteal arteries for the treatment of obstructive lesions of synthetic or native arteriovenous dialysis fistulae.
Global Percutaneous Transluminal Angioplasty Balloons Catheter Market – Impact of Coronavirus (COVID-19) Pandemic
The pandemic-triggered lockdown resulted in the closure of industrial establishments, except for the manufacturing of essential commodities, and disruptions in the supply chain of products. The COVID-19 pandemic has affected the economy in three main ways: by directly affecting production and demand, creating disruptions in distribution channels, and causing financial impact on firms and financial markets.
Supply chain and manufacturing activities in North America, Asia Pacific, Europe, and other regions have been disrupted due to lockdown. Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which are required to ensure safety in hospitals and provide treatment to patients with other diseases. This has also negatively impacted the overall healthcare market.
The COVID-19 pandemic highly affected interventional cardiology practice, as there were disruptions in multiple aspects, ranging from cath lab personnel availability and the need for personal protection to the management of acute coronary syndrome (ACS) patients and massive reduction in procedural activity.
Thus, the COVID-19 has hampered the global percutaneous transluminal angioplasty balloon catheter market.
Browse 54 Market Data Tables and 43 Figures spread through 258 Pages and in-depth TOC on “Global Percutaneous Transluminal Angioplasty Balloons Catheter Market”- Forecast to 2028, Global Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type (Standard PTA Balloons, High Pressure PTA Balloons, Scoring PTA Balloons, Cutting Balloons, Drug Coated Balloon, Lithotripsy Balloons, and Others (Stent graft balloon catheter)), by Material (Polyurethane, Nylon, and Others), by Application (Peripheral Artery Disease and Coronary Artery Disease), by Diameter Size (1 to 4 mm, 4 to 8 mm, and > 8 mm), by End User (Hospitals, Cardiology Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Percutaneous Transluminal Angioplasty Balloons Catheter Market, click the link below:
The increasing prevalence of coronary heart disease is expected to aid in the global percutaneous transluminal angioplasty balloons catheter market growth over the forecast period. For instance, according to an article published by the Centers for Disease Control and Prevention in September 2021, coronary heart disease is the most common type of heart disease, which caused approximately 360,900 deaths in 2019 in the U.S.
Key Takeaways of the Global Percutaneous Transluminal Angioplasty Balloons Catheter Market:
- The global percutaneous transluminal angioplasty balloons catheter market is expected to exhibit a CAGR of 8.3% during the forecast period due to increasing adoption of inorganic growth strategies such as partnerships by the key market players. For instance, in April 2020, Cook Medical, a division of Cook Group, and Surmodics, Inc., a global leader in surface modification technologies for intravascular medical devices, announced that the companies had entered into an agreement in which Cook Medical will distribute new products of Surmodics, such as hydrophilic percutaneous transluminal angioplasty (PTA) balloon catheters that can be used over 0.014-inch and 0.018-inch wire guides.
- Among diameter sizes, the 4 to 8 mm segment accounted for the largest market share in the global percutaneous transluminal angioplasty balloons catheter market in 2021, owing to strong focus of market players on gaining approval from regulatory bodies. For instance, in November 2020, Boston Scientific Corporation, a manufacturer of medical devices, announced that it had received the U.S. Food and Drug Administration (FDA) approval for Ranger Drug-Coated Balloon developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA). Ranger Drug-coated PTA Balloon Catheter is available in diameters of 4 -7 mm.
- On the basis of regions, North America accounted for the largest market share in the global percutaneous transluminal angioplasty balloons catheter market in 2021. The early adoption of newer products, well-established healthcare infrastructure, and presence of key market players such as Cook Medical, Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic Plc, etc. are expected to drive the market growth in the region. For instance, in August 2019, B. Braun Interventional Systems Inc., a company offering medical devices, announced Breakthrough Device Designation from the U.S. FDA for SeQuent Please ReX drug-coated PTCA balloon catheter for the treatment of coronary in-stent restenosis (ISR).
- Major players operating in the global percutaneous transluminal angioplasty balloons catheter market include Cook Group, Medtronic Plc., Becton, Dickinson and Company, Abbott Laboratories, Koninklijke Philips N.V., ENDOCOR GmbH, Cardinal Health, NIPRO, Terumo Corporation, Boston Scientific Corporation, Surmodics, Inc., Teleflex Incorporated, BIOTRONIK SE & Co. KG, Biomerics, Shockwave Medical Inc., Microport Scientific Corporation, Nordson Corporation, and S3V Vascular Technologies Pvt. Ltd.
